OPKO Health, Inc.

OPK

US68375N1037

Healthcare Facilities & Services

Delayed Nasdaq Other stock markets 10:30:00 03/07/2024 pm IST			5-day change	1st Jan Change
1.215 ^USD	+0.41%		-5.08%	-19.54%

07/05	Earnings Flash (OPK) OPKO HEALTH Posts Q1 Revenue $173.7M, vs. Street Est of $183M	MT
07/05	Opko Health, Inc. Provides Earnings Guidance for the Second Quarter of 2024	CI

OPKO Health, Inc. Provides Revenue Guidance for the Third Quarter of 2023

August 04, 2023 at 02:00 am IST

OPKO Health, Inc. provided revenue guidance for the third quarter of 2023. For the period, the company expected total revenue between $165 million and $180 million.

Latest news about OPKO Health, Inc.

Earnings Flash (OPK) OPKO HEALTH Posts Q1 Revenue $173.7M, vs. Street Est of $183M	08/05	MT
Opko Health, Inc. Provides Earnings Guidance for the Second Quarter of 2024	08/05	CI
Transcript : OPKO Health, Inc., Q1 2024 Earnings Call, May 07, 2024	08/05
OPKO Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets	28/03	MT
Transcript : OPKO Health, Inc. - Shareholder/Analyst Call	28/03
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	20/03	CI
Opko Health Insider Bought Shares Worth $444,300, According to a Recent SEC Filing	15/03	MT
Opko Health Insider Bought Shares Worth $463,750, According to a Recent SEC Filing	14/03	MT
Opko Health Insider Bought Shares Worth $559,380, According to a Recent SEC Filing	13/03	MT
Barrington Cuts Price Target on OPKO Health to $1.50 From $2, Maintains Outperform Rating	28/02	MT
Transcript : OPKO Health, Inc., Q4 2023 Earnings Call, Feb 27, 2024	28/02
Earnings Flash (OPK) OPKO HEALTH Reports Q4 Revenue $181.9M, vs. Street Est of $177.5M	28/02	MT
OPKO Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/02	CI
Drugmakers deepen efforts to tap into booming market for obesity drugs	27/02	RE
Opko Health Insider Bought Shares Worth $991,700, According to a Recent SEC Filing	22/02	MT
HealthSnap, Inc. announced that it has received $24.999999 million in funding from a group of investors	21/02	CI
OPKO Health, Inc. Announces the Cessation of Alexis Borisy as Member of the Board of Directors and Member of Compensation Committee of the Board	10/02	CI
NextPlat Preparing to Launch Opko Health Store on Alibaba's Tmall Global Platform	05/02	MT
Opko Health Insider Bought Shares Worth $488,650, According to a Recent SEC Filing	20/01	MT
Opko Health Insider Bought Shares Worth $386,200, According to a Recent SEC Filing	19/01	MT
Opko Health Insider Bought Shares Worth $954,300, According to a Recent SEC Filing	17/01	MT
Opko Health Insider Bought Shares Worth $480,379, According to a Recent SEC Filing	12/01	MT
Transcript : OPKO Health, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM	11/01
OPKO Health Closes Private Offering of $230 Million Convertible Notes Due 2029	10/01	MT

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.

Sector

Healthcare Facilities & Services

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for OPKO Health, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.215 USD

Average target price

4.25 USD

Spread / Average Target

+249.79%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
OPKO HEALTH, INC.	-19.54%	847M
SONIC HEALTHCARE LIMITED	-19.73%	8.22B
RADNET, INC.	+70.43%	4.38B
DR. LAL PATHLABS LIMITED	+12.76%	2.81B
SYNLAB AG	-2.28%	2.66B
NEOGENOMICS, INC.	-15.14%	1.75B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-58.41%	1.74B
FLEURY S.A.	-16.52%	1.47B
METROPOLIS HEALTHCARE LIMITED	+24.33%	1.24B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-50.73%	1.03B

Medical & Diagnostic Laboratories

OPKO Health, Inc.

Equities

OPK

US68375N1037

Healthcare Facilities & Services

OPKO Health, Inc. Provides Revenue Guidance for the Third Quarter of 2023

Latest news about OPKO Health, Inc.

Chart OPKO Health, Inc.

Company Profile

Income Statement Evolution

Ratings for OPKO Health, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Medical & Diagnostic Laboratories